Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12606000064505
Ethics application status
Approved
Date submitted
8/02/2006
Date registered
15/02/2006
Date last updated
15/02/2006
Type of registration
Prospectively registered
Titles & IDs
Public title
A Randomised Double Blind Placebo Controlled Trial of Site Specific Clonidine Patches In Treatment of Neuropathic Wound Pain Following Caesarean Section
Query!
Scientific title
A Randomised Double Blind Placebo Controlled Trial of Site Specific Clonidine Patches In Treatment of Neuropathic Wound Pain Following Caesarean Section
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Neuropathic wound pain following caesarean section
1027
0
Query!
Condition category
Condition code
Reproductive Health and Childbirth
1101
1101
0
0
Query!
Other surgery
Query!
Neurological
1102
1102
0
0
Query!
Pain management
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Clonidine patch applied to the site of neuropathic pain . Patch to be applied for 24 hours. (clonidine dose in patch = 2.5mg)
Query!
Intervention code [1]
888
0
Treatment: Drugs
Query!
Comparator / control treatment
placebo
Query!
Control group
Placebo
Query!
Outcomes
Primary outcome [1]
1469
0
Reduction of neuropathic pain
Query!
Assessment method [1]
1469
0
Query!
Timepoint [1]
1469
0
Measured at 24 hours post application of the clonidine patch
Query!
Secondary outcome [1]
2635
0
Reduction of antineuropathic pain medication
Query!
Assessment method [1]
2635
0
Query!
Timepoint [1]
2635
0
Measured at 24 hours post application of clonidine patch
Query!
Eligibility
Key inclusion criteria
patients who fit the following criteria: The diagnostic criteria of Hayes et al (2002) have been modified for this study. They propose that 5 of 8 features suggestive of neuropathic pain need to be present for the diagnosis to be made. One of these features (history consistent with nerve injury) is considered satisfied in all caesarian section patients in view of their surgical history. Another, (associated autonomic features) is neither sought nor seen frequently in caesarian section patients. We are therefore left with 4 of 6 features as follows:1.Pain in the absence of evidence of ongoing tissue damage2.Character of pain from any of: burning, stabbing, pulsing.3.Paroxysmal or spontaneous pain4.Presence of any of: allodynia, hyperalgesia, hyperpathia5.Pain within an area of sensory deficit6.Associated dysaesthesias
Query!
Minimum age
Not stated
Query!
Query!
Maximum age
Not stated
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1.Known previous hypersensitivity to clonidine or clonidine patches2.Current treatment for other neuropathic pain states3.Current treatment with clonidine, tricyclic antidepressants, anti convulsants, or oral sodium channel blockers eg mexiletine.4.Patients who would normally require an interpreter for informed consent or to properly interpret pain scoring.5.Patients with a vertical surgical incision.6.Patients with severe bradyarrythmia due to sick sinus syndrome or 2nd or 3rd degree AV block.7.Discharge or transfer anticipated within following 24 hours8.Refusal of informed consent.9.Patients currently on other antihypertensive agents.10.Patients in whom an ilioinguinal nerve block has been performed.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
sealed envelopes
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
computer generated randomisation
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
subjects, therapists and outcome assessors all blinded
Query!
Phase
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
20/03/2006
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
60
Query!
Accrual to date
Query!
Final
Query!
Recruitment outside Australia
Country [1]
283
0
New Zealand
Query!
State/province [1]
283
0
Query!
Funding & Sponsors
Funding source category [1]
1205
0
Hospital
Query!
Name [1]
1205
0
Anaesthetic dept, Womens Health, Auckland City Hospital
Query!
Address [1]
1205
0
Query!
Country [1]
1205
0
New Zealand
Query!
Primary sponsor type
Individual
Query!
Name
Tim Short
Query!
Address
Query!
Country
Query!
Secondary sponsor category [1]
1064
0
Government body
Query!
Name [1]
1064
0
Auckland Health
Query!
Address [1]
1064
0
Query!
Country [1]
1064
0
New Zealand
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
2545
0
Auckland Hospital
Query!
Ethics committee address [1]
2545
0
Query!
Ethics committee country [1]
2545
0
New Zealand
Query!
Date submitted for ethics approval [1]
2545
0
Query!
Approval date [1]
2545
0
08/11/2005
Query!
Ethics approval number [1]
2545
0
NTX/05/03/012 (A+ 3137)
Query!
Summary
Brief summary
There will be a research nurse who will randomise and initiate patient treatments (placebo or clonidine) as described below, but who will not participate in any other aspect of the patient’s care or assessment. A trained collaborator will pack sixty serially numbered envelopes with either active or placebo patch and cover, together with instructions for its use. The envelopes will be prepared in such a way that the contents cannot be determined by feel. They will be held in a box in series order in the anaesthetic department. A master copy of the randomisation code will be held on computer by this collaborator. Each envelope will contain a slip stating that the patient is to be given clonidine or placebo. In the case of a clonidine allocation the envelope will contain one clonidine TTS-1 patch whose expiry is known to extend beyond the duration of the trial. In the case of a placebo allocation the envelope will contain one square shaped inert patch which will enable the research nurse to simulate application of a patch to the affected area in the placebo patients. Finally, the envelope will contain an opaque occlusive dressing that will be placed over the clonidine patch or bandaid dressing so that neither the patient nor any other staff will be able to determine the treatment allocation. Once consent is completed, a trained collaborator will draw the next consecutive envelope from the file in the department. They must record the trial number from the envelope in the space provided on the patient’s trial data form (Appendix 2). They will then visit the patient to apply the patch or “placebo patch” as directed by the pain team staff. The patch must be applied directly over the maximally tender point adjacent to the wound. Collaborators must ensure the patient does not watch what they are doing, and should refer to the patch as the “trial patch” rather than a clonidine patch, placebo or any other term that might influence the patient’s perception of their treatment allocation. The patch will remain in place for 24 hours. The dressing and patch will be removed by a collaborator(research nurse), and the identity of the underlying patch will continue to be concealed from the patient and trial investigators.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
36352
0
Query!
Address
36352
0
Query!
Country
36352
0
Query!
Phone
36352
0
Query!
Fax
36352
0
Query!
Email
36352
0
Query!
Contact person for public queries
Name
10077
0
Jane Suckling
Query!
Address
10077
0
Anaesthetic Department
Womens Health
Auckland City Hospital
Level 9
Grafton Road
Grafton Auckland
Query!
Country
10077
0
New Zealand
Query!
Phone
10077
0
+64 2 1468832
Query!
Fax
10077
0
Query!
Email
10077
0
[email protected]
Query!
Contact person for scientific queries
Name
1005
0
Fran Storr
Query!
Address
1005
0
Anaesthetic Department
Womens Health
Auckland City Hospital
Level 9
Grafton Road
Grafton Auckland
Query!
Country
1005
0
New Zealand
Query!
Phone
1005
0
+64 2 1492235
Query!
Fax
1005
0
Query!
Email
1005
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF